AFP
LUCD icon

Ausdal Financial Partners’s Lucid Diagnostics LUCD Stock Holding History

Ausdal Financial Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9K Buy
+12,075
New +$15.4K ﹤0.01% 982

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Ausdal Financial Partners's LUCD Position: Q1 2026 in Review

Ausdal Financial Partners opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 12,075 shares worth $13.9K. The stake represents ﹤0.01% of the portfolio and ranks #982 among its holdings.

103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Ausdal Financial Partners held 12,075 shares of Lucid Diagnostics worth $13.9K as of Q1 2026.
  • Lucid Diagnostics was a new Ausdal Financial Partners position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of Ausdal Financial Partners's portfolio in Q1 2026, its #982 holding.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.